The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer. READ MORE
Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer.
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.
Research in Review
New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options.
Researchers used Surveillance, Epidemiology, and End Results registry data to review the costs associated with treatment plans consistent with NCCN guidelines.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.